AC Immune SA

( )
ACIU After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
LLYEli Lilly & Co. 0.13%365.731.1%$1192.85m
JNJJohnson & Johnson 0.02%177.270.7%$1097.56m
MRKMerck & Co., Inc. 0.87%108.430.7%$1003.85m
PFEPfizer Inc. 0.78%49.600.9%$989.10m
ABBVAbbVie, Inc. -0.80%158.341.9%$899.56m
BMYBristol-Myers Squibb Co. -0.13%79.141.1%$749.90m
AZNAstraZeneca Plc 0.06%66.211.0%$360.38m
IDXXIDEXX Laboratories, Inc. -2.74%400.103.9%$216.54m
GSKGSK Plc -0.65%33.770.3%$200.71m
HZNPHorizon Therapeutics Plc -0.36%78.005.4%$200.65m
NVSNovartis AG -0.04%87.680.2%$189.81m
CTLTCatalent, Inc. 13.32%46.911.9%$185.64m
NVONovo Nordisk A/S 2.08%121.270.1%$158.80m
ALNYAlnylam Pharmaceuticals, Inc. -1.66%209.208.0%$156.50m
SNYSanofi 0.33%45.540.2%$122.13m

Company Profile

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.